Actinic Keratosis Clinical Trial
Official title:
Open Uncontrolled Validation Study for the German Version of the Actinic Keratosis Quality of Life Questionnaire (AKQoL)
The objective of this study is to translate the "AKQoL"-questionnaire which measures the
quality of life of patients with actinic keratosis into German and to validate it for the
Swiss population.
By using the technique of cognitive interviewing the investigators are focussing on the
patients' understanding of the questions. The first session of cognitive interviews will
show, where there is need for improvement in terms of misinterpreted phrases or vaguely
worded questions. The goal is to rephrase the questions according to the feedback of the
patients. The revised version will then be presented to a new population.
Actinic keratosis is a UV-induced skin disease, which presents as a reddish, squamous and
sometimes itchy lesion. Actinic keratosis seems to have a negative impact on patients'
quality of life. Esmann et al. elaborated on patients with actinic keratosis from Zealand,
Denmark a questionnaire which measures the quality of life.
The objective of this study is to translate this questionnaire into German and to validate
it for the Swiss population. This questionnaire might become part of a planned national
register for data collection of patients with AK.
The investigators will assess the content validity of the questionnaire by using the
technique of cognitive interviewing. The investigators are going to talk 34 patients with AK
from the department of Dermatology, University Hospital Zurich through the translated
version. Thereby, the investigators are focusing on the patients' understanding of the
questions.
The first session of cognitive interviews will show, where there is need for improvement in
terms of misinterpreted phrases or vaguely worded questions. The goal is to rephrase the
questions in the sense that they become more clear and are understood by different
interviewee in the same way. The revised version will then be presented to a new population.
The performance of cognitive interview sessions and revisions will continue until the survey
will be approved by at least 80% of the respondents.
;
Intervention Model: Single Group Assignment, Masking: Open Label
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03013647 -
Daylight Photodynamic Therapy for Actinic Keratosis and Skin Field Cancerization
|
N/A | |
| Completed |
NCT02674048 -
Metvix Daylight PDT in Actinic Keratosis
|
||
| Completed |
NCT02239679 -
Controlled Study of the Occurrence of Actinic Keratosis on the Face After Cryotherapy + Aminolevulinic Acid (ALA) Photodynamic Therapy
|
Phase 2 | |
| Completed |
NCT02421471 -
PMS to Evaluate the Safety and Efficacy of Picato® Gel
|
||
| Completed |
NCT01686152 -
Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis
|
Phase 3 | |
| Completed |
NCT01449513 -
PEP005 Gel - Biological Effects in Actinic Keratosis Assessed by Reflectance Confocal Microscopy
|
Phase 1 | |
| Completed |
NCT01444989 -
Development and Validation of a Quality of Life Instrument for Actinic Keratosis
|
N/A | |
| Terminated |
NCT01525329 -
Combination Therapy With 5-Fluorouracil and Photodynamic Therapy in Post-transplant Premalignant Skin Disease
|
Phase 3 | |
| Terminated |
NCT01203878 -
Treatment of Actinic Keratoses of the Face With Imiquimod 3.75% Cream Followed by Photodynamic Therapy
|
Phase 4 | |
| Completed |
NCT00989313 -
A Long Term Follow up Study of Patients Who Have Complete Clearance of Their Actinic Keratosis (AK) Lesions at the Day 57 Visit in the PEP005-028 Study
|
Phase 3 | |
| Completed |
NCT00306800 -
Metvix PDT Versus Vehicle PDT With Aktilite CL128 Lamp in Patients With Actinic Keratosis on the Face and Scalp
|
Phase 3 | |
| Completed |
NCT00375739 -
Study to Determine the Safety of PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses
|
Phase 2 | |
| Completed |
NCT03285490 -
A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on Actinic Keratosis on Face or Scalp (AK004)
|
Phase 3 | |
| Completed |
NCT03319251 -
Biomarker Database Registry for Photodynamic Therapy
|
||
| Completed |
NCT02866695 -
Safety and Efficacy of Ingenol Mebutate Gel 0.015% for Treatment of AK on the Face in Solid Organ Transplant Recipients
|
Phase 4 | |
| Completed |
NCT02952898 -
Study Comparing GDC 695 and Diclofenac Sodium Gel, 3% in Subjects With Actinic Keratoses
|
Phase 3 | |
| Completed |
NCT02984072 -
Menthol for PDT Pain Relief
|
Phase 4 | |
| Recruiting |
NCT03684772 -
Topical Ionic Contra-Viral Therapy in Actinic Keratosis
|
Phase 2 | |
| Completed |
NCT02878382 -
Potential Impact of Patient Vitamin D Status in AK Response to MAL-PDT
|
N/A | |
| Completed |
NCT02902822 -
Tele-dermatology of Skin Cancer in a Cohort of Local Health Authority Employees in the Province of Bergamo
|
N/A |